Bizarre Patents
Pillow with retractable umbrella
A pillow assembly having a supporting assembly and a retractable umbrella assembly that is easily transportable and allows a user to support his/her head while covering their face from sunlight.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8071104 | Neovascular-targeted immunoconjugates Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 imm... | 12/06/2011 |
| 7887809 | Neovascular-targeted immunoconjugates Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 imm... | 02/15/2011 |
| 7858092 | Neovascular-targeted immunoconjugates Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 imm... | 12/28/2010 |
| 7435790 | Dihydroxypropyl cysteine peptide and agent containing this peptide The invention relates to a S-(2,3-dihydroxypropyl)-cysteine peptide which has two long-chain fatty acids bonded in the form of esters at the dihydroxypropyl group, and which has the following sequence: DhcGN NDE SNI SFK EK. The invention relat... | 10/14/2008 |
| 7387772 | Chimeric, human and humanized anti-CSAP monoclonal antibodies The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. ... | 06/17/2008 |
| 7320786 | Photodynamic therapy treatment for eye disease This invention discloses methods, kits, and instructions to treat neovasculature diseases of the eye through the administration of a targeted photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate photosensitizing ... | 01/22/2008 |
| 7303749 | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at le... | 12/04/2007 |
| 7285314 | Steam barrier film A steam barrier film comprising at least one inorganic gas barrier layer on a polyalkylene naphthalate resin substrate film in which the glass transition temperature (Tg) of the polyalkylene naphthalate resin is from 70 to 150° C. and the steam barrier film compris... | 10/23/2007 |
| 7226601 | Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate A method for the treatment of a disease in a mammal by administering a therapeutically effective amount of a conjugate comprising a biospecific affinity counterpart and a peptide, wherein the peptide contains an amino acid sequence that is derived from staphylococca... | 06/05/2007 |
| 7220778 | Methods and devices for epithelial protection during photodynamic therapy Methods for preventing damage to epithelial tissue during PDT induced using a photosensitizing agent or pre-photosensitizing agent are provided. The methods of the present invention utilize spatial confinement to control photoactivation of the photoactive species to... | 05/22/2007 |
| 7214787 | Recombinant vaccine against botulinum neurotoxin This invention is directed to preparation and expression of synthetic genes encoding polypeptides containing protective epitopes of botulinum neurotoxin (BoNT). The invention is also directed to production of immunogenic peptides encoded by the synthetic genes, as w... | 05/08/2007 |
| 7189395 | Complexes of immunoglobulins and polysaccharides for oral and transmucosal absorption The present invention relates to complexes consisting of immunoglobulins and polysaccharides for oral and transmucosal use. The polysaccharides comprised in the complexes according to the invention form an envelope which protects and carries immunoglobulins a... | 03/13/2007 |
| 7166719 | Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy Provided herein are compounds for detection, diagnosis and treatment of target tissues or target compositions, including hyperproliferative tissues such as tumors, using photodynamic methods. In particular, photosensitizer compounds that collect in hyperproliferativ... | 01/23/2007 |
| 7147849 | Pharmaceutical formulation A pharmaceutical formulation containing at least one protein-containing substance and at least one substance selected from the group of compatible solutes. ... | 12/12/2006 |
| 7135185 | Conserved motif of hepatitis C virus E2/NS1 region Immunogenic compositions comprising an immunogenic polypeptide and a pharmaceutically acceptable vehicle are described. The immunogenic polypeptide comprises the amino acid sequence Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-... | 11/14/2006 |
| 7109182 | Synthetic oligomannosides, preparation and uses thereof A pharmaceutical composition including a therapeutically effective amount of at least one oligomannoside produced by chemical synthesis which is homologous to a wall oligomannoside of an infectious organism or pathogen, or a derivative thereof, and a pharmaceuticall... | 09/19/2006 |
| 7070991 | Cells expressing a CD4-IgG2 chimeric heterotetramer This invention provides an expression vector encoding a CD4-gamma2 chimeric heavy chain homodimer. This invention also provides an expression vector encoding the heavy chains of a CD4-IgG2 chimeric heterotetramer. Finally, this invention provides an expression vecto... | 07/04/2006 |
| 7060495 | Fusion proteins for prodrug activation The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is ... | 06/13/2006 |
| 7053210 | Efficient synthesis of pyropheophorbide a and its derivatives A process for the preparation of pyropheophorbide a and its derivatives, including 3-devinyl-3-(1′-hexyloxy)ethyl-pyropheophorbide-a, otherwise known as HPPH, is provided. The process involves treating chlorin e6, in the form of its trimethyl ester, wit... | 05/30/2006 |
| 7019197 | Pesticidal fusions Disclosed are polynucleotides encoding a pesticidal fusion polypeptide comprising (i) a toxin domain; and (ii) a heterologous binding domain capable of binding non-specifically to a cell membrane without disrupting that membrane. Preferably the toxin domain is deriv... | 03/28/2006 |
| 7018395 | Photodynamic treatment of targeted cells The present invention is drawn to methods for photodynamic therapy (PDT) of a target cell, target tissue or target composition in a mammalian subject, using a therapeutically effective amount of a targeted substance, which is either a targeted photosensitizing agent... | 03/28/2006 |
| 6998125 | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis The present invention provides a synergistic composition and methods for treating neoplastic or cancerous growths as well as for treating such patients in order to restore or boost hematopoiesis. The present invention comprises administration of the combination of a... | 02/14/2006 |
| 6977075 | Photosensitizer conjugates for targeting intracellular pathogens The methods of the invention can be used to treat mycobacterial infections, or any disease or disorder that is caused by (or aggravated by) an intracellular pathogen. Accordingly, the invention features methods for treating a subject who has a disorder that is assoc... | 12/20/2005 |
| 6969517 | Recombinant tumor specific antibody and use thereof The invention provides a family of antibodies that specifically bind the human epithelial cell adhesion molecule. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a ... | 11/29/2005 |
| 6962701 | Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of us... | 11/08/2005 |
| 6962694 | Cytolysis of target cells by superantigen conjugates inducing T-cell activation A method for inactivating target cells in the presence of T cells by bringing the two types of cells in contact with a superantigen (SAG) in the presence of an immune modulator, characterized in that at least one of the superantigen and the immune modulator is in th... | 11/08/2005 |
| 6808930 | Therapeutic agents An agent comprising a protein complex comprising an oligomeric form of α-lactalbumin (MAL) and a further reagent which is combined with MAL such that it is carried into the nucleoplasm of cells which are susceptible to MAL. Agents of the type, where the further rea... | 10/26/2004 |
| 6749853 | Combined methods and compositions for coagulation and tumor treatment Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecif... | 06/15/2004 |
| 6652852 | Chimeric antibody with specificity to human B cell surface antigen A chimeric antibody with human constant region and murine variable region, having specificity to a 35 kDA polypeptide (Bp35(CD20)) expressed on the surface of human B cells, methods of production, and uses.... | 11/25/2003 |
| 6610298 | Photosensitzer conjugates for targeting intracellular pathogens The methods of the invention can be used to treat mycobacterial infections, or any disease or disorder that is caused by (or aggravated by) an intracellular pathogen. Accordingly, the invention features methods for treating a subject who has a disorder th... | 08/26/2003 |
| 6573242 | Dihydroxypropyl cysteine peptide and agent containing this peptide The invention relates to a S-(2,3-dihydroxypropyl)-cysteine peptide which has two long-chain fatty acids bonded in the form of esters at the dihydroxypropyl group, and which has the following sequence: Dhc GN NDE SNI SFK EK (SEQ ID No 1) ... | 06/03/2003 |
| 6562801 | PpGpp and pppGpp as immunomodulatory agents The present invention relates generally to the fields of immunopreventive therapy and vaccine development. More particularly, it concerns compositions and methods of use of the bacterial nucleotides ppGpp and pppGpp and their analogs as adjuvants that can... | 05/13/2003 |
| 6548644 | Site protected protein modification Processes for conjugating proteins with polyethylene glycol are disclosed. The disclosed processes provide modified proteins having little or no decrease in their activity and include the steps of protecting one or more sites on the protein, contacting th... | 04/15/2003 |
| 6548067 | Antigenic constructs of major histocompatibility complex class I antigens with specific carrier molecules, the preparation and use thereof Antigenic constructs which result from linkage of major histocompatibility complex (MHC) class I antigens with specific carrier molecules are described. The linkage is effected N- or C-terminally by covalent bonding or, for example, in the case of non-cov... | 04/15/2003 |
| 6514498 | Modified/chimeric superantigens and their use A conjugate between a target-seeking moiety and a modified superantigen, characterized in that the superantigen is a wild-type superantigen (SA I) in which an amino acid residue in a superantigen region (region I) determining binding to TCR, referably TCR... | 02/04/2003 |
| 6406679 | Use of HL-60-related lectins in drug delivery and detection of lectin-expressing cells Pharmaceutical compositions useful in the treatment of autoimmune conditions include as an active ingredient a soluble lectin having a molecular weight of about 14 kilodaltons or a fragment thereof. The lectin or fragment binds ଲ-galactoside-contain... | 06/18/2002 |
| 6368598 | Drug complex for treatment of metastatic prostate cancer A drug complex for delivery of a drug or other agent to a target cell, comprising a targeting carrier molecule which is selectively distributed to a specific cell type or tissue containing the specific cell type; a linker which is acted upon by a molecule... | 04/09/2002 |
| 6348195 | Method for treating cancers The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines ... | 02/19/2002 |
| 6315997 | Use of modified antibodies with human milk fat globule specificity An analogue peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such ... | 11/13/2001 |
| 6258360 | Prodrugs activated by targeted catalytic proteins Prodrugs that are activated by and conjugated to a catalytic antibody conjugated to a moiety that binds to a tumor cell population are provided.... | 07/10/2001 |
